TEVA241122C27500
- 0.00
- 0.000.00%
Teva Pharmaceutical Industries Newsroom
Press Release: Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 10th, 2024
Teva Pharmaceutical Industries Options Spot-On: On November 27th, 63,244 Contracts Were Traded, With 622.89K Open Interest
Unusual Options Activity: AAL, COIN and Others Attract Market Bets, AAL V/OI Ratio Reaches 75.0
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25
Goldman's Hedge Fund VIP List: AMZN, VST, CRM, BABA, and More
Unusual Options Activity: TEVA, MDT and Others Attract Market Bets, TEVA V/OI Ratio Reaches 322.6
Teva Pharmaceutical Industries (NYSE:TEVA) Shareholders Are Still up 85% Over 3 Years Despite Pulling Back 4.0% in the Past Week
US Manufacturing Index Rises To 43, Highest Since 2020
Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
Unusual Options Activity: CCK, CMG and Others Attract Market Bets, CCK V/OI Ratio Reaches 179.2
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Druckenmiller's Duquesne Closes Some Media Holdings, Loads Into Regional Banks, Among Q3 Trades
Assertio Stock Gains Amid Clash With Activist Investor, Q3 Earnings
UBS Upgrades Teva Pharmaceutical Industries(TEVA.US) to Buy Rating, Maintains Target Price $26
Teva to Present at the Jefferies London Healthcare Conference
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
UBS Downgrades Teva Pharmaceutical Industries(TEVA.US) to Hold Rating, Maintains Target Price $26
US MOVERS&SHAKERS Nov 04-Nov 08, 2024
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $23